Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Conditions
Brief summary
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVE: I. To assess the objective response rate (complete and partial responses), following the administration of cabozantinib for 12 weeks in patients with locally advanced biopsy-proven non-metastatic clear cell renal cell carcinoma (ccRCC) prior to undergoing surgery. SECONDARY OBJECTIVES: I. To assess the safety, and tolerability of neoadjuvant cabozantinib. II. To determine the clinical outcome (disease-free survival \[DFS\], overall survival \[OS\]) of patients with non-metastatic ccRCC who treated with neoadjuvant cabozantinib. III. To evaluate the surgery related outcomes. IV. To evaluate correlative studies, including biomarkers, quality of life, and frailty/sarcopenia assessment of patients with non-metastatic ccRCC who treated with neoadjuvant cabozantinib. OUTLINE: Patients receive cabozantinib orally (PO) once daily (QD) for 12 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months.
Interventions
DRUGCabozantinib
Given PO
Sponsors
Emory University
Exelixis
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with renal mass consistent with a clinical stage ≥ T3Nx or TanyN+ or deemed unresectable by surgeon. * Renal cell carcinoma with clear cell component on pre-treatment biopsy of the primary tumor. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. * Patients must have adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment: * Absolute neutrophil count (ANC) ≥ 1500/mm³ (≥ 1.5 GI/L) without granulocyte colony-stimulating factor support. * White blood cell count ≥ 2500/mm³ (≥ 2.5 GI/L). * Platelets ≥ 100,000/mm³ (≥ 100 GI/L) without transfusion. * Hemoglobin ≥ 9 g/dL. * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 x upper limit of normal (ULN). ALP ≤ 5 x ULN with documented bone metastases. * Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN). * Serum albumin ≥ 2.8 g/dl. * Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft-Gault equation: * Males: (140 - age) x weight (kg)/(serum creatinine \[mg/dL\] × 72) * Females: \[(140 - age) x weight (kg)/(serum creatinine \[mg/dL\] × 72)\] × 0.85 * Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol). * No hormonal therapy, chemotherapy, immunotherapy, or any other systemic therapy for a malignancy, in the 5 years prior to current study enrollment. * Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment. * Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (ie, females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons. * Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.
Exclusion criteria
* Evidence of metastatic disease on pre-treatment imaging. * The subject has received of any type of cytotoxic, biologic or other systemic anticancer therapy for kidney cancer. * The subject has received any other type of investigational agent within 28 days before the first dose of study treatment. * Known brain metastases or cranial epidural disease. * Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel). Allowed anticoagulants are the following: * Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted. * Low-dose low molecular weight heparins (LMWH) are permitted. * Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor. * The subject has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test ≥ 1.3 × the laboratory ULN within 14 days before the first dose of study treatment. * The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: * Cardiovascular disorders: * Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias. * Uncontrolled hypertension defined as sustained blood pressure (BP) \> 150 mm Hg systolic or \> 100 mm Hg diastolic despite optimal antihypertensive treatment. * Stroke (including transient ischemic attack \[TIA\]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (eg, deep venous thrombosis, pulmonary embolism) within 6 months before first dose. * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: * The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, active inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction. * Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose. * Clinically significant hematemesis, or hemoptysis of \> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose. * Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation. * Other clinically significant disorders that would preclude safe study participation. * Serious non-healing wound/ulcer/bone fracture. * Uncompensated/symptomatic hypothyroidism. * Moderate to severe hepatic impairment (Child-Pugh B or C). * Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (eg, simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible. * Prolongation of the QT corrected for HR using Fridericia's method (QTcF) interval defined as \> 500 msec per electrocardiogram (ECG) within 28 days before first dose of study treatment. Note: If a single ECG shows a QTcF with an absolute value \> 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility. * Pregnant or lactating females. * Inability to swallow tablets. * Previously identified allergy or hypersensitivity to components of the study treatment formulations. * Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy. Patients with Gleason 6 (3+3) prostate cancer with previous treatment or on active surveillance may also be allowed on protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | At 12 weeks after cabozantinib dose | Objective response rate will be evaluated using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria. All tumor measurements must be recorded in centimeters. For target lesions, a complete response (CR) is defined as the disappearance of all target lesions. A partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free Survival (DFS) | From time of surgery to first tumor recurrence or death, assessed up to 3 years | Disease-free survival will be defined as the interval between time of surgery and the first tumor recurrence or death. Patients will be censored at time of last follow-up. Disease-free survival will be estimated with the Kaplan-Meier method. |
| Overall Survival (OS) | From time of surgery to death from any cause, assessed up to 3 years | For overall survival, death from any cause will be defined as the event. Patients will be censored at time of last follow-up. Overall survival will be estimated with the Kaplan-Meier method. |
| Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Baseline and weeks 6 and 12 after treatment initiation | Quality of life will be studied using the Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) questionnaire. The questionnaire consists of 19 statements that patients answer on a 0-4 scale ("Not at all" to "Very much"). Per the instrument's official scoring guidelines, items are then reverse scored as needed and summed to create a final score ranging from 0-76, where 76 indicates the best quality of life and 0 indicates the worst. |
| Frailty Assessment | Baseline and weeks 6 and 12 after treatment initiation | Frailty assessment will be studied using the Fried Frailty score. Domains to be assessed include shrinking, weakness, exhaustion, low activity, and slow walking speed. Scored on a total scale of 0-25 (from 5 variables, each 0-5). 0 = not frail, 25 = most frail. |
| Sarcopenia Assessment | Baseline and week 12 after treatment initiation | Sarcopenia assessment will be done by using baseline and week 12 scans via SliceOmatic version 5.0 by TomoVision program. Cross-sectional skeletal muscle area (SMA) at the L3 vertebra will be segmented to calculate the Skeletal Muscle Index (SMI = SMA cm² / height m²). Sarcopenia is defined as an SMI at or below the 25th percentile of age- and sex-specific reference values from the Fintelmann et al. (2024) Framingham Heart Study cohort. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMehmet Asim Bilen, MD
Emory University
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Cabozantinib) Patients receive cabozantinib orally once daily for 12 weeks in the absence of disease progression or unacceptable toxicity. The assigned starting dose for cabozantinib is 60 mg/day. Two dose reduction levels of cabozantinib are permitted
Cabozantinib: Given PO | 17 |
| Total | 17 |
Baseline characteristics
| Characteristic | Treatment (Cabozantinib) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 4 Participants |
| Age, Categorical Between 18 and 65 years | 13 Participants |
| Age, Continuous | 57 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 14 Participants |
| Region of Enrollment United States | 17 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 17 |
| other Total, other adverse events | 17 / 17 |
| serious Total, serious adverse events | 4 / 17 |
Outcome results
Primary
Objective Response Rate (ORR)
Objective response rate will be evaluated using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria. All tumor measurements must be recorded in centimeters. For target lesions, a complete response (CR) is defined as the disappearance of all target lesions. A partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
Time frame: At 12 weeks after cabozantinib dose
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (cabozantinib) | Objective Response Rate (ORR) | Partial Response | 6 Participants |
| Treatment (cabozantinib) | Objective Response Rate (ORR) | Stable Disease | 11 Participants |
Secondary
Disease-free Survival (DFS)
Disease-free survival will be defined as the interval between time of surgery and the first tumor recurrence or death. Patients will be censored at time of last follow-up. Disease-free survival will be estimated with the Kaplan-Meier method.
Time frame: From time of surgery to first tumor recurrence or death, assessed up to 3 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (cabozantinib) | Disease-free Survival (DFS) | 12 month survival rate | 82.4 percentage of participants |
| Treatment (cabozantinib) | Disease-free Survival (DFS) | 24 month survival rate | 76.5 percentage of participants |
Secondary
Frailty Assessment
Frailty assessment will be studied using the Fried Frailty score. Domains to be assessed include shrinking, weakness, exhaustion, low activity, and slow walking speed. Scored on a total scale of 0-25 (from 5 variables, each 0-5). 0 = not frail, 25 = most frail.
Time frame: Baseline and weeks 6 and 12 after treatment initiation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Treatment (cabozantinib) | Frailty Assessment | Week 6 | 1.82 score on a scale | Standard Deviation 1.47 |
| Treatment (cabozantinib) | Frailty Assessment | Week 12 | 2.06 score on a scale | Standard Deviation 1.39 |
| Treatment (cabozantinib) | Frailty Assessment | Baseline | 1.18 score on a scale | Standard Deviation 1.33 |
Secondary
Overall Survival (OS)
For overall survival, death from any cause will be defined as the event. Patients will be censored at time of last follow-up. Overall survival will be estimated with the Kaplan-Meier method.
Time frame: From time of surgery to death from any cause, assessed up to 3 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (cabozantinib) | Overall Survival (OS) | 12 month survival rate | 94.1 percentage of participants |
| Treatment (cabozantinib) | Overall Survival (OS) | 24 month survival rate | 88.2 percentage of participants |
Secondary
Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire
Quality of life will be studied using the Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) questionnaire. The questionnaire consists of 19 statements that patients answer on a 0-4 scale (Not at all to Very much). Per the instrument's official scoring guidelines, items are then reverse scored as needed and summed to create a final score ranging from 0-76, where 76 indicates the best quality of life and 0 indicates the worst.
Time frame: Baseline and weeks 6 and 12 after treatment initiation
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Baseline | 60 score on a scale |
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Week 6 | 48.6 score on a scale |
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Week 12 | 48.5 score on a scale |
Secondary
Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire
Quality of life will be studied using the Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) questionnaire. The questionnaire consists of 19 statements such as I have a lack of energy and I have pain which are answered on a scale of 0-4, with 0 being Not at all and 4 being Very much. The scale is 0-76 (0 = worst QoL, 76 = best QoL).
Time frame: Baseline and weeks 6 and 12 after treatment initiation
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Baseline | 64 score on a scale |
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Week 6 | 51 score on a scale |
| Treatment (cabozantinib) | Quality of Life Assessment: Functional Assessment of Cancer Therapy-Kidney Specific Index-19 (FKSI-19) Questionnaire | Week 12 | 48 score on a scale |
Secondary
Sarcopenia Assessment
Sarcopenia assessment will be done by using baseline and week 12 scans via SliceOmatic version 5.0 by TomoVision program. Cross-sectional skeletal muscle area (SMA) at the L3 vertebra will be segmented to calculate the Skeletal Muscle Index (SMI = SMA cm² / height m²). Sarcopenia is defined as an SMI at or below the 25th percentile of age- and sex-specific reference values from the Fintelmann et al. (2024) Framingham Heart Study cohort.
Time frame: Baseline and week 12 after treatment initiation
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (cabozantinib) | Sarcopenia Assessment | Participants with Sarcopenia (baseline) | 9 Participants |
| Treatment (cabozantinib) | Sarcopenia Assessment | Participants with Sarcopenia (week12) | 9 Participants |